Another hypothesis is that individuals included in our study may already be at particularly high cardiovascular risk, with 38% of our cohort experiencing prior ischemic heart disease, 83% and 88% receiving angiotensin-converting enzyme/angiotensin receptor blocker and lipid-lowering agents, respectively, and 72% being treated with anticoagulants. The gene discussed is ACE; the disease is coronary artery disorder.